RESUMEN
Lung adenocarcinoma (LUAC) is a unique lung cancer subtype that is responsive to several therapeutic agents. The KRAS gene is the second most frequently mutated gene in LUAC and the majority of KRAS mutations are one of three classical activating mutations (G12, G13, and Q61). Recently, other types of "minor" KRAS mutation have been identified among LUAC patients and some may have similar transforming activities to those of the classical KRAS mutations. Here we describe minor KRAS mutations in LUAC patients, some of which (A66T, A66V, and G75E) may have tumor-forming activity in mouse embryonic fibroblasts in an allograft model. RNA-Seq analysis revealed that mouse embryonic fibroblasts overexpressing these three minor KRAS mutations have distinct expression profiles compared with overexpression of the wild type but similar expression profiles compared with overexpression of the classical KRAS mutants. Our results indicate that some of the minor KRAS mutations cause varying tumor formation activity and are important targets for developing anti-RAS agents as chemotherapeutic agents.
Asunto(s)
Adenocarcinoma del Pulmón/genética , Neoplasias Pulmonares/genética , Mutación Puntual , Proteínas Proto-Oncogénicas p21(ras)/genética , Adenocarcinoma del Pulmón/patología , Animales , Carcinogénesis/genética , Carcinogénesis/patología , Fibroblastos/metabolismo , Fibroblastos/patología , Humanos , Neoplasias Pulmonares/patología , Ratones , Modelos Moleculares , TranscriptomaRESUMEN
Mitogen-activated protein kinase phosphatase 5 (MKP-5)/DUSP10 acts as a phosphatase of stress-activated kinases (JNK and p38), but its activity towards ERK has not been demonstrated. In the present study we observed that MKP-5 interacts with ERK, retains it in the cytoplasm, suppresses its activation and downregulates ERK-dependent transcription. These data suggested a novel MKP-5 function as a scaffold protein for the ERK pathway. We analyzed MKP-5 gene expression in several tumors, and found that it is frequently upregulated in colorectal but not in lung and breast cancer, suggesting its association with the malignant phenotype of colon cancer.
Asunto(s)
Carcinoma/enzimología , Neoplasias del Colon/enzimología , Fosfatasas de Especificidad Dual/metabolismo , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Regulación Enzimológica de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Fosfatasas de la Proteína Quinasa Activada por Mitógenos/metabolismo , Línea Celular Tumoral , Fosfatasas de Especificidad Dual/genética , Genes Reporteros , Humanos , Proteínas Quinasas JNK Activadas por Mitógenos/metabolismo , Luciferasas/biosíntesis , Luciferasas/genética , Sistema de Señalización de MAP Quinasas , Fosfatasas de la Proteína Quinasa Activada por Mitógenos/genética , Fosforilación , Procesamiento Proteico-Postraduccional , Elementos de Respuesta , Transcripción Genética , Regulación hacia Arriba , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismoRESUMEN
Cell division cycle 25 (CDC25) phosphatases are cell-cycle regulatory proteins which are overexpressed in a significant number of human cancers. This study evaluated the role of CDC25 phosphatases in human glioma proliferation. Upregulation of CDC25A was observed in human glioma specimens and human glioma cell lines. Comparison of expression levels of CDC25A and CDC25B messenger ribonucleic acid (RNA) to Ki-67 labeling index in glioma tissues found that Ki-67 labeling index was significantly correlated with the expression of CDC25A, but not with that of CDC25B. Depletion of CDC25A by small interfering RNA and inhibition of CDC25 suppressed cell proliferation and induced apoptosis in glioma cell lines, indicating that CDC25A is a potential target for the development of new therapy for glioma.
Asunto(s)
Neoplasias Encefálicas/metabolismo , Expresión Génica/fisiología , Glioma/metabolismo , Antígeno Ki-67/metabolismo , ARN Mensajero/metabolismo , Estadística como Asunto , Fosfatasas cdc25/genética , Adulto , Anciano , Anciano de 80 o más Años , Benzoquinonas/farmacología , Neoplasias Encefálicas/genética , Caspasa 3/metabolismo , Caspasa 7/metabolismo , Muerte Celular/genética , Línea Celular Tumoral , Proliferación Celular , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/farmacología , Etilaminas/farmacología , Femenino , Glioma/genética , Humanos , Antígeno Ki-67/genética , Masculino , Persona de Mediana Edad , Nitrocompuestos/farmacología , ARN Interferente Pequeño/genética , ARN Interferente Pequeño/metabolismo , Tiazoles/farmacología , Factores de Tiempo , Transfección/métodos , Regulación hacia Arriba/genética , Adulto Joven , Fosfatasas cdc25/antagonistas & inhibidores , Fosfatasas cdc25/metabolismoRESUMEN
O-acetylserine(thiol) lyase (OASTL), a key enzyme of the plant sulfur assimilatory pathway, catalyses the formation of cysteine from sulfide and O-acetylserine. Transgenic hybrid poplar (Populus sieboldi x P. grandidentata 'Y63') plants expressing cys1, encoding a wheat cytosolic OASTL, were developed in order to examine the role of this enzyme in thiol production following hydrogen sulfide or sulfur dioxide exposure and in the extent of damage induced in the plants by these pollutants. The transgenic cys1 plants accumulated up to several-fold higher cysteine and glutathione levels and were significantly more resistant in terms of foliar damage to the pollutants than WT plants. The transgenic poplar also showed higher tolerance to sulfite and hydrogen peroxide and, interestingly, accumulated several-fold higher sulfite reductase transcripts than WT plants in response to sulfur dioxide. These data clearly demonstrate the important role of OASTL and the sulfur reduction pathway in sulfur and oxidative stress amelioration, and support the notion that transgenic trees resistant to such pollutants can be generated for phytoremediation strategies.
